Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Simon

Showing results (41-50 of 1,327) with videos related to

Pageof 133
Sort By:
Frontiers in Neuroscience|November 5, 2008
Merging of the sensesSidney S Simon
Neuropsychiatric Disease and Treatment|April 4, 2023
Appropriate Outcome Choice Requires Certainty About Symptom Patterns of Patient Subgroups - We are Still Left with Unexplained Heterogeneity [Response To Letter]Maria S Simon
Annals of the Rheumatic Diseases|October 16, 2002
Pharmacovigilance: towards a better understanding of the benefit to risk ratioL S Simon
Current Opinion in Rheumatology|June 1, 1990
Toxicity of nonsteroidal anti-inflammatory drugsL S Simon
The American Journal of Medicine|July 2, 1999
Role and regulation of cyclooxygenase-2 during inflammationL S Simon
Clinical Cornerstone|February 26, 2000
Osteoarthritis: a reviewL S Simon
Arthritis and Rheumatism|June 21, 2001
COX-2 inhibition: an advance or only pharmaceutical "hype"?L S Simon
Osteoarthritis and Cartilage|May 9, 2006
Osteoarthritis, imaging and guidance for approval of a structural "indication"L S Simon
Swiss Medical Weekly|October 7, 2005
The COX-2 inhibitors: a reasoned review of the dataLee S Simon
Hospital & Community Psychiatry|May 1, 1972
Boarding home operators participate in workshopC S Simon
Pageof 133

Showing results (41-50 of 1,327) with videos related to

Sort By:
Pageof 133
Frontiers in Neuroscience|November 5, 2008
Merging of the sensesSidney S Simon
Neuropsychiatric Disease and Treatment|April 4, 2023
Appropriate Outcome Choice Requires Certainty About Symptom Patterns of Patient Subgroups - We are Still Left with Unexplained Heterogeneity [Response To Letter]Maria S Simon
Annals of the Rheumatic Diseases|October 16, 2002
Pharmacovigilance: towards a better understanding of the benefit to risk ratioL S Simon
Current Opinion in Rheumatology|June 1, 1990
Toxicity of nonsteroidal anti-inflammatory drugsL S Simon
The American Journal of Medicine|July 2, 1999
Role and regulation of cyclooxygenase-2 during inflammationL S Simon
Clinical Cornerstone|February 26, 2000
Osteoarthritis: a reviewL S Simon
Arthritis and Rheumatism|June 21, 2001
COX-2 inhibition: an advance or only pharmaceutical "hype"?L S Simon
Osteoarthritis and Cartilage|May 9, 2006
Osteoarthritis, imaging and guidance for approval of a structural "indication"L S Simon
Swiss Medical Weekly|October 7, 2005
The COX-2 inhibitors: a reasoned review of the dataLee S Simon
Hospital & Community Psychiatry|May 1, 1972
Boarding home operators participate in workshopC S Simon
Pageof 133